Therapeutic Paradigm Changes in Myasthenia Gravis and Amyotrophic Lateral Sclerosis
Year: 2026
Type: article
Abstract: The treatment paradigm for neuromuscular diseases, especially myasthenia gravis and amyotrophic lateral sclerosis, has recently shifted with the emergence of mechanism-based and precision therapies. In myasthenia gravis, improved understanding of antibody-mediated pathology has enabled the clinical adoption of targeted immunotherapies, including complement inhibitors and neonatal Fc receptor antagonists, resulting in meaningful benefits for refractory disease and a shift beyond conventional immunosuppression. In amyotrophic lateral sclerosis, while multidisciplinary care remains fundamental, recent advances highlight a gradual move toward precision medicine through platform trial designs, biomarker-informed evaluation, and gene-specific molecular therapies for selected patient subgroups. Together, these developments reflect a paradigm shift from uniform treatment strategies to individualized, pathophysiology-driven clinical decision-making. This review summarizes recent guideline updates and key clinical trial evidence, illustrating how advances in immunopathology, genetics, and trial methodology are redefining contemporary neuromuscular care.
Author: Seong-il Oh
Institutions: Kyung Hee University, Kyung Hee University Medical Center
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7160072220